398 related articles for article (PubMed ID: 25130190)
1. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
[TBL] [Abstract][Full Text] [Related]
2. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
4. Effects of
Yang FF; Xue TL; Gao C; Wu Y; Lin W; Li J; Zhang RD; Zheng HY; Liu SG
Pharmacogenomics; 2022 Oct; 23(15):821-834. PubMed ID: 36193736
[No Abstract] [Full Text] [Related]
5. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide study of methotrexate clearance replicates SLCO1B1.
Ramsey LB; Panetta JC; Smith C; Yang W; Fan Y; Winick NJ; Martin PL; Cheng C; Devidas M; Pui CH; Evans WE; Hunger SP; Loh M; Relling MV
Blood; 2013 Feb; 121(6):898-904. PubMed ID: 23233662
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
[TBL] [Abstract][Full Text] [Related]
8. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.
Skärby TV; Anderson H; Heldrup J; Kanerva JA; Seidel H; Schmiegelow K;
Leukemia; 2006 Nov; 20(11):1955-62. PubMed ID: 16990760
[TBL] [Abstract][Full Text] [Related]
9. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
10. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
12. Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia.
Suzuki R; Fukushima H; Noguchi E; Tsuchida M; Kiyokawa N; Koike K; Ma E; Takahashi H; Kobayashi C; Nakajima-Yamaguchi R; Sakai A; Saito M; Iwabuchi A; Kato K; Nakao T; Yoshimi A; Sumazaki R; Fukushima T
Pediatr Int; 2015 Aug; 57(4):572-7. PubMed ID: 25939871
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.
Liu SG; Gao C; Zhang RD; Zhao XX; Cui L; Li WJ; Chen ZP; Yue ZX; Zhang YY; Wu MY; Wang JX; Li ZG; Zheng HY
Oncotarget; 2017 Jun; 8(23):37761-37772. PubMed ID: 28525903
[TBL] [Abstract][Full Text] [Related]
14. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
Treviño LR; Shimasaki N; Yang W; Panetta JC; Cheng C; Pei D; Chan D; Sparreboom A; Giacomini KM; Pui CH; Evans WE; Relling MV
J Clin Oncol; 2009 Dec; 27(35):5972-8. PubMed ID: 19901119
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
[TBL] [Abstract][Full Text] [Related]
16. SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy.
Eldem İ; Yavuz D; Cumaoğullari Ö; İleri T; Ünal İnce E; Ertem M; Doğanay Erdoğan B; Bindak R; Özdağ H; Şatiroğlu-Tufan NL; Uysal LZ
J Pediatr Hematol Oncol; 2018 Jul; 40(5):e289-e294. PubMed ID: 29683944
[TBL] [Abstract][Full Text] [Related]
17. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
18. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
19. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]